Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Thomas E. Seay"'
Autor:
SL Chia, D L Wickerham, Barry C. Lembersky, Mark L. Graham, James L. Wade, Sandra M. Swain, BT Hennessy, Soonmyung Paik, Charles E. Geyer, Adam Brufsky, Thomas E. Seay, Eleftherios P. Mamounas, SR Dakil, Louis Fehrenbacher, Hanna Bandos, Edward C. McCarron, Gamini S. Soori, Norman Wolmark
Publikováno v:
Cancer Research. 77:S1-05
Background: Extending adjuvant endocrine therapy (tx) after 5 yrs of tamoxifen (Tam) with either Tam or an AI improves disease-free survival (DFS) in early-stage breast cancer (BC). However, optimal duration of adjuvant AI tx beyond 5 yrs is unknown.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1f154fb7eacf3c7e9e59b2fe70471b66
https://doi.org/10.1158/1538-7445.sabcs16-s1-05
https://doi.org/10.1158/1538-7445.sabcs16-s1-05
Autor:
Mary Cianfrocca, Eleftherios P. Mamounas, Patricia A. Ganz, Timothy F. Wozniak, Gamini S. Soori, Keren Sturtz, Norman Wolmark, Kathy S. Albain, Adam Brufsky, Louis Fehrenbacher, Laura A. Vallow, Patrick W Whitworth, Joseph P. Costantino, Richard G. Margolese, Judith O. Hopkins, Howard M. Gross, Reena S. Cecchini, Thomas B. Julian, Thomas E. Seay
Publikováno v:
Lancet (London, England), vol 387, iss 10021
Summary Background Ductal carcinoma in situ is currently managed with excision, radiotherapy, and adjuvant hormone therapy, usually tamoxifen. We postulated that an aromatase inhibitor would be safer and more effective. We therefore undertook this tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad6e1eb4f627e416930a984223cbdb62
https://doi.org/10.1016/s0140-6736(15)01168-x
https://doi.org/10.1016/s0140-6736(15)01168-x
Autor:
Louis Fehrenbacher, Timothy F. Wozniak, Thomas E. Seay, Patrick W Whitworth, Mary Cianfrocca, Richard G. Margolese, Joseph P. Costantino, Adam Brufsky, Howard M. Gross, Reena S. Cecchini, Laura A. Vallow, Norman Wolmark, Thomas B. Julian, Judith O. Hopkins, Gamini S. Soori, Eleftherios P. Mamounas, Keren Sturtz, Kathy S. Albain, Patricia A. Ganz
Publikováno v:
Lancet (London, England), vol 387, iss 10021
BackgroundThe NSABP B-35 trial compared 5 years of treatment with anastrozole versus tamoxifen for reducing subsequent occurrence of breast cancer in postmenopausal patients with ductal carcinoma in situ. This report assesses the effect of these drug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55cb94f525d41f7f8fb6a78043290850
https://doi.org/10.1016/s0140-6736(15)01169-1
https://doi.org/10.1016/s0140-6736(15)01169-1
Autor:
D Lawerence Wickerham, Barry C. Lembersky, Thomas E. Seay, Hanna Bandos, James L. Wade, Stephen Chia, Edward C. McCarron, Norman Wolmark, Charles E. Geyer, Mark L. Graham, Gamini S. Soori, Sandra M. Swain, Priya Rastogi, Louis Fehrenbacher, Eleftherios P. Mamounas, Soonmyung Paik, Janice M. Walshe, Shaker R. Dakhil, Jeon Hyeon Jeong, Adam Brufsky
Publikováno v:
Cancer Research. 80:GS4-01
Background: In the NSABP B-42 trial we aimed to determine whether 5 yrs of letrozole (L) v placebo (P) improves DFS in patients (pts) who have completed 5 yrs of hormonal therapy (tx). 3966 postmenopausal pts with stage I-III, hormone-receptor+ BC, d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d5a06908c6af419de1f3428aed411679
https://doi.org/10.1158/1538-7445.sabcs19-gs4-01
https://doi.org/10.1158/1538-7445.sabcs19-gs4-01
Autor:
Sandra M. Swain, James L. Wade, Stephen Chia, Charles E. Geyer, Louis Fehrenbacher, Janice M. Walshe, Gamini S. Soori, Eleftherios P. Mamounas, Hanna Bandos, D. Lawrence Wickerham, Jong-Hyeon Jeong, Soonmyung Paik, Edward C. McCarron, Mark L. Graham, Shaker R. Dakhil, Adam Brufsky, Priya Rastogi, Barry C. Lembersky, Norman Wolmark, Thomas E. Seay
Publikováno v:
The Lancet. Oncology. 20(1)
The optimal duration of extended therapy with aromatase inhibitors in patients with postmenopausal breast cancer is unknown. In the NSABP B-42 study, we aimed to determine whether extended letrozole treatment improves disease-free survival after 5 ye
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a5fadd1360df8f0ec3875469ade2f7b
https://pubmed.ncbi.nlm.nih.gov/30614468
https://pubmed.ncbi.nlm.nih.gov/30614468
Autor:
George P. Kim, Steven R. Alberts, Joel M. Reid, Thomas E. Seay, Gist H. Farr, John K. Camoriano, Bruce W. Morlan, James R. Enger, David B. Johnson
Publikováno v:
American Journal of Clinical Oncology. 35:418-423
Few effective options are available for the treatment of unresectable hepatocellular carcinoma (HCC). Several phase I trials suggest promising activity of a combination of gemcitabine and docetaxel.Patients with unresectable or metastatic HCC were tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32631cb6e143fc0c7e83b6d508b4609b
https://doi.org/10.1097/coc.0b013e318219863b
https://doi.org/10.1097/coc.0b013e318219863b
Autor:
Greg Yothers, Ramesh K. Ramanathan, Michael O’Connell, J. Philip Kuebler, Gamini S. Soori, Linda H. Colangelo, Barbara A. Conley, Patrick J. Flynn, Louis Fehrenbacher, James N. Atkins, H. Samuel Wieand, Norman Wolmark, Michael Findlay, Thomas E. Seay, Roy E. Smith, N. J. Petrelli, Edward A. Levine, John L. Zapas, Lauren K. Colman, J. Wendall Goodwin, Keith S. Lanier
Publikováno v:
Journal of Clinical Oncology. 25:2198-2204
Purpose This phase III clinical trial evaluated the impact on disease-free survival (DFS) of adding oxaliplatin to bolus weekly fluorouracil (FU) combined with leucovorin as surgical adjuvant therapy for stage II and III colon cancer. Patients and Me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::261e4defe075c520cc1cf329a8967472
https://doi.org/10.1200/jco.2006.08.2974
https://doi.org/10.1200/jco.2006.08.2974
Autor:
Michael J. O'Connell, Thomas E. Seay, Jeffrey K. Giguere, Greg Yothers, Lauren K. Colman, Linda H. Colangelo, Norman Wolmark, Barry C. Lembersky, M. Ernest Marshall, Andrew D. Jacobs, Roy E. Smith, H. Samuel Wieand, Atilla Soran, Nicholas J. Petrelli
Publikováno v:
Journal of Clinical Oncology. 24:2059-2064
Purpose The primary aim of this study was to compare the relative efficacy of oral uracil and tegafur (UFT) plus leucovorin (LV) with the efficacy of weekly intravenous fluorouracil (FU) plus LV in prolonging disease-free survival (DFS) and overall s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aebd7b44cde1c5960d53abb57b27b52e
https://doi.org/10.1200/jco.2005.04.7498
https://doi.org/10.1200/jco.2005.04.7498
Autor:
E. David Crawford, Mario A. Eisenberger, Burton M. Needles, Neel Hammond, Thomas E. Seay, Robert C. Flanigan, Danika Lew, Louis E. Schroder
Publikováno v:
Urologic Oncology: Seminars and Original Investigations. 6:145-148
Twenty-two eligible patients with advanced renal carcinoma were treated with suramin utilizing a fixed dose regimen. Therapy was reasonably well tolerated with 3 of 22 patients (14%) developing grade 4 toxicity and 11 of 22 patients (50%) having a ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b17c8b4bf14db02d3097d5ce8074664f
https://doi.org/10.1016/s1078-1439(00)00126-5
https://doi.org/10.1016/s1078-1439(00)00126-5
Autor:
Mansoor N. Saleh, Malcolm J. Moore, Jeffrey R. Infante, Thomas J. Ervin, Eric Van Cutsem, Josep Tabernero, Daniel D. Von Hoff, Marion Harris, Francis P. Arena, Manuel Hidalgo, Xinyu Wei, E. Gabriela Chiorean, Wen Wee Ma, Nathan Bahary, David Goldstein, Daniel A. Laheru, Sergei Tjulandin, Scot Dowden, Ramesh K. Ramanathan, Michele Reni, Thomas E. Seay, Jose Iglesias, Markus F. Renschler
BACKGROUND In a phase 1–2 trial of albumin-bound paclitaxel (nab-paclitaxel) plus gemcitabine, substantial clinical activity was noted in patients with advanced pancreatic cancer. We conducted a phase 3 study of the efficacy and safety of the combi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bca36e04c6f2f6f441b1299ecfc2cc4
https://europepmc.org/articles/PMC4631139/
https://europepmc.org/articles/PMC4631139/
